Symptoms and impact of COPD assessed by an electronic diary in patients with moderate-to-severe COPD: Psychometric results from the SHINE study

International Journal of COPD

Volumn 10, Issue , 2015, Pages 79-94

  Kulich, Károly ^a   Keininger, Dorothy L ^a   Tiplady, Brian ^b   Banerji, Donald ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b EResearch Technologies Ltd   (United Kingdom)

Author keywords

Dyspnea; Health status; Patient reported outcomes; Psychometric assessment; QVA149

Indexed keywords

ADULT; AGED; ARTICLE; CHEST TIGHTNESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOCUMENTATION; DYSPNEA; ELECTRONIC DIARY; FEMALE; HUMAN; INTERNAL CONSISTENCY; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MUCUS; PATIENT COMPLIANCE; PREDICTION; PSYCHOMETRY; SYMPTOM; TEST RETEST RELIABILITY; VALIDITY; WHEEZING; CLINICAL TRIAL; COMPLICATION; COST OF ILLNESS; DAILY LIFE ACTIVITY; DRUG EFFECTS; FACTORIAL ANALYSIS; HEALTH STATUS; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PSYCHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY; SELF REPORT; SEVERITY OF ILLNESS INDEX; TIME; VERY ELDERLY;

BRONCHODILATING AGENT;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; COST OF ILLNESS; DYSPNEA; FACTOR ANALYSIS, STATISTICAL; FEMALE; HEALTH STATUS; HUMANS; LUNG; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; PSYCHOMETRICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; SELF REPORT; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84920911794     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S73092     Document Type: Article

References (29)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2014 update [webpage on the Internet]. Global Initiative for Chronic Obstructive Lung Disease, Inc.; 2014. Available from: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. Accessed July 11, 2014.
2. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care. 2003;48(12):1204-1213.
3. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991;85(Suppl B):25-31.
4. Deshpande PR, Rajan S, Sudeepthi BL, Abdul Nazir CP. Patient-reported outcomes: A new era in clinical research. Perspect Clin Res. 2011;2(4): 137-144.
5. Byrom B, Tiplady B, editors. ePRO: Electronic Solutions for Patient-Reported Data. Surrey: Gower; 2010.
6. Ireland AM, Wiklund I, Hsieh R, Dale P, O'Rourke E. An electronic diary is shown to be more reliable than a paper diary: results from a randomized crossover study in patients with persistent asthma. J Asthma. 2012; 49(9):952-960.
7. Bjorner JB, Rose M, Gandek B, Stone AA, Junghaenel DU, Ware JE. Method of administration of PROMIS scales did not significantly impact score level, reliability, or validity. J Clin Epidemiol. 2014; 67(1):108-113.
8. Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient non-compliance with paper diaries. BMJ. 2002;324(7347): 1193-1194.
9. Stull DE, Leidy NK, Parasuraman B, Chassany O. Optimal recall periods for patient-reported outcomes: challenges and potential solutions. Curr Med Res Opin. 2009;25(4):929-942.
10. Jones P, Miravitlles M, van der Molen T, Kulich K. Beyond FEV1 in COPD: a review of patient-reported outcomes and their measurement. Int J Chron Obstruct Pulmon Dis. 2012;7:697-709.
11. US Department of Health and Human Services Food and Drug Administration. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims; 2009. Silver Spring, MD: FDA. Available from: www.fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM193282.pdf. Accessed February 18, 2014.
12. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484-1494.
13. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51-60.
14. Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med. 2013;107(10):1558-1567.
15. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013; 1(3):199-209.
16. Baldwin MJ, Kulich K, Tiplady B, Gwaltney C, Cline J. Evaluation of an electronic daily diary for measuring morning symptoms in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187: A2517.
17. Baldwin M, Kulich K, Tiplady B, Gwaltney C, Cline J. Symptoms and impact of COPD assessed by a handheld electronic diary. Poster presented at: 2013 Meeting of the European Respiratory Society; September 7-11, 2013; Barcelona, Spain. Poster P4903.
18. Mahler DA, Faryniarz K, Tomlinson D, et al. Impact of dyspnea and physiologic function on general health status in patients with chronic obstructive pulmonary disease. Chest. 1992;102(2):395-401.
19. Tsiligianni I, Kocks J, Tzanakis N, Siafakas N, van der Molen T. Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations. Prim Care Respir J. 2011;20(3):257-268.
20. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6): 751-758.
21. O'Connor BP. SPSS and SAS programs for determining the number of components using parallel analysis and velicer's MAP test. Behav Res Methods Instrum Comput. 2000;32(3):396-402.
22. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86(2):420-428.
23. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest. 2000;118(5):1278-1285.
24. Jones PW, Donohue JF, Nedelman J, Pascoe S, Pinault G, Lassen C. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res. 2011;12:161.
25. Kerns K, Decker SN. Multifactorial assessment of reading disability: identifying the best predictors. Percept Mot Skills. 1985;60(3): 747-753.
26. Fraenkel L, Falzer P, Fried T, et al. Measuring pain impact versus pain severity using a numeric rating scale. J Gen Intern Med. 2012;27(5): 555-560.
27. Morren M, van Dulmen S, Ouwerkerk J, Bensing J. Compliance with momentary pain measurement using electronic diaries: a systematic review. Eur J Pain. 2009;13(4):354-365.
28. Mahler DA, Ward J, Waterman LA, McCusker C, Zuwallack R, Baird JC. Patient-reported dyspnea in COPD reliability and association with stage of disease. Chest. 2009;136(6):1473-1479.
29. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York, NY: Academic Press; 1977.